WST
West Pharmaceutical Services
$329.71
▲ 0.5%Updated Today 7:15 PM ET
▲ Up 50.5% over the last 12 months
Market Cap
$23.28B
P/E
42.93x
Forward P/E (est.)
36.53x
ROE
17.9%
Revenue Growth
11.2%
EPS Growth
17.5%
Profit Margin
16.9%
FCF Yield
2.7%
Debt / Equity
0.07x
ROIC
14.0%
Interest Coverage
64.99x
Current Ratio
2.71x
Dividend Yield
0.3%
Implied Growth (rev. DCF)
6.8%
Rating Score
56/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what WST's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. WST trades near $329.71, above its 50-day average ($303.72) and 200-day average ($271.23). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 52 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. WST's is $7.91 (~2.4% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month WST found buyers near $299.72 (support) and sellers near $336.82 (resistance); its 52-week range is $206.80–$336.82. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
West Pharmaceutical Services (WST) is a large-cap company in the Health Care Supplies industry, part of the Health Care sector of the S&P 500, with a market value around $23.28B.
In its latest reported year it generated about $3.07B in revenue and $493.70M in net profit.
Our model rates WST Neutral (56/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
2.1%
Revenue moved from $2.83B in 2021 to $3.07B in 2025, a 2.1% compound annual growth rate. The most recent year grew a steady 11.2% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
35.9%
Operating Margin
19.0%
Net Margin
16.1%
ROE
17.9%
West Pharmaceutical Services keeps about 16.9% of each sales dollar as net profit, with a 35.9% gross margin and 19.0% operating margin. Return on equity is 17.9% and return on invested capital about 14.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$202.80M
Net Debt
-$318.60M
Net cash position
Net Debt / EBITDA
-0.54x
Debt / Equity
0.07x
Leverage: debt-to-equity is 0.1x, and operating profit covers interest about 65.0x, with a current ratio of 2.7x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $202.80M of total debt against $521.40M of cash.
Operating CF
$754.80M
Free Cash Flow
$468.90M
FCF Margin
15.3%
In the latest year West Pharmaceutical Services produced about $754.80M of operating cash flow and $468.90M of free cash flow after capital spending. That is a free-cash-flow yield of about 2.7% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
42.93x
P/S
7.62x
P/B
6.2x
EV / EBITDA
29.73x
WST trades at 42.9x trailing earnings (about 36.5x on estimated forward earnings), 7.6x sales, and 6.2x book value. Reverse-engineering today's price implies the market expects roughly 6.8% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How WST stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), WST ranks #25 of 59 by our overall rating. It trades at a premium versus the sector on earnings (42.9x P/E vs. 25.4x median) with a higher return on equity (17.9% vs. 14.9%) and faster revenue growth (11.2% vs. 7.9%).
P/E vs sector
42.9x
median 25.4x
ROE vs sector
17.9%
median 14.9%
Growth vs sector
11.2%
median 7.9%
Sector rank
#25
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$305.02 – $504.46
vs. $329.71 today · expected CAGR -2% – 9%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $3.41B | $3.79B | $4.20B | $4.67B | $5.18B |
| Net income | $545.96M | $606.02M | $672.68M | $746.67M | $828.81M |
| EPS | $7.73 | $8.58 | $9.52 | $10.57 | $11.73 |
| Share price (low) | $200.93 | $223.03 | $247.56 | $274.79 | $305.02 |
| Share price (high) | $332.30 | $368.85 | $409.43 | $454.47 | $504.46 |
| CAGR (low–high) | -39% / 1% | -18% / 6% | -9% / 7% | -4% / 8% | -2% / 9% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for WST:
- Revenue is growing 11.2% a year, a sign of real demand.
- High net margins (16.9%) point to pricing power or efficiency.
- Strong return on equity (17.9%) shows capital is put to work well.
- A conservative balance sheet (debt/equity 0.1x) lowers risk.
The case against WST:
- A rich 42.9x earnings multiple prices in a lot of growth.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 42.9x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: West Pharmaceutical Services is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 42.9x earnings, which our model scores Neutral (56/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.